GenSpera Patents its New Cancer Treatment and Imaging Methods in the US
GenSpera Inc. is a leader in developing prodrug therapeutics that can be used for treating cancer. The company’s patent lawyers have just announced that the USPTO has given them patent grants for their new cancer treatment and imaging methods. The patent titled “Methods and compositions for the detection of cancer” was awarded on the 8th of July in 2014, and carries the patent number US 8,772,226 B2.
Ingenuity
The patent that GenSpera’s patent attorneys have so convincingly won in the USPTO courts contains claims for the composition of prodrugs made with and containing thapsigargin that can be used for cancer treatment. These prodrugs can be radiolabelled and activated using specific enzymes such as Prostate Specific Membrane Antigen (PSMA), Prostate Specific Antigen (PSA) or Human Glandular Kallikrein 2 (hK2). The activated prodrugs can then be used in the detection, imaging, and the treatment procedure of various cancers.
Unlike Obamacare – GenSpera Delivers
According to the patent attorneys representing GenSpera, the patent that has been granted by the USPTO also contains the claims for the methods utilized in the cancer treatment with the aid of these radiolabelled prodrugs. The prodrugs can be used on humans and the exact mechanism of use and treatment has been specifically elaborated in the patent that has been filed and granted to GenSpera by the USPTO.
The patent claims were co-invented by Drs. Samuel Denmeade, John Isaacs and Soren Brogger Christensen. All three of the doctors are members of the Scientific Advisory Board at GenSpera.
GenSpera’s CEO, Craig Dionne who is also a PhD in cancer research said that the claims made in the patent effectively elucidate the new wave of cancer treatment known as G-202. The G-202 treatment is being explored extensively with regard to liver cancer and glioblastoma Phase II clinical trials, and Dionne is very hopeful that the technology described in the patent when brought into the market can “aid in the selection of patients most likely to benefit from G-202 treatment”.
GenSpera and companies like this would already have the cure for cancer if they were not taxed so much. GenSpera is getting it done. GenSpera is not a patent troll!
Understanding Prodrugs
A prodrug is a medication that can be administered to a patient in an inactive or less than fully active form, and which is then converted to its active form inside the patient’s body through normal metabolic processes like hydrolysis of an ester to produce a drug. Technically speaking, a prodrug is the chemical precursor of the drug and the compound has all the properties of the drug, only in an inert form. Instead of administering the drug directly into the patient’s body, the use of a prodrug is recommended in certain situations and it can greatly enhance the way the drug is absorbed by the body and distributed via normal body pathways.
Dedicated Research
Most drugs are absorbed via the gastrointestinal tract but the absorption rate can be poor. Instead, administering a prodrug can improve the bio-availability of the drug and can also improve upon the normal interaction between the drug and the cells or processes in the body that it is meant to effect. In certain cases, the administration of a prodrug can also reduce over-absorption of a drug since the rate of absorption is completely dependent on the bodily functions and it is assumed that our bodies would intuitively know how much of the drug to absorb and at what times.
In diseases like cancer, where the prevalent method of treatment is chemotherapy, which has its own share of side effects, prodrugs can be a boon if successful. They can help the body heal in a very natural and intrinsic way without causing the additional harm that chemotherapy and radiation can cause. GenSpera is one of the leading producers in the market for such cancer-related prodrugs that can be used to bring about a revolutionary change in the treatment of cancer all over the world.
